Five months, five companies: Life-changing ideas, game-changing support. Accelerate@Babraham, the bio-entrepreneurial incubator initiative founded and developed by the Babraham Research Campus - supported by key industry and investor organisations - opens applications for its 2021/22 cohort today.
AKL Research and Development (AKLRD), a UK pharmaceutical company which develops novel solutions for inflammatory diseases with a high unmet need, unveils new data at the Osteoarthritis Research Society International (OARSI) Virtual World Congress (April 29 – May 1) indicating its investigational oral osteoarthritis (OA) drug APPA can modulate cellular function, reduce inflammation and inhibit bone resorption associated with joint degradation caused by the disease.
Laval, Quebec, March 23, 2021 – WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants.
Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the
American Association for Cancer Research (AACR), highlighting the multi-faceted anti-cancer activity of
MDX-124 - the company’s proprietary therapeutic antibody.
Respiratory viruses such as SARS-CoV-2 often catalyse an overactive immune response that leads to a life-threatening cycle, known as a cytokine storm. Analysing cytokine responses from patients has unearthed glaringly important differences in how SARS-CoV-2 affects cytokines compared to other common respiratory viruses.
Medannex Ltd (Edinburgh) this week received multiple awards in recognition of notable successes in
several key areas. The late-stage biopharmaceutical company, developing novel treatments for cancers
and autoimmune diseases, was declared the winner in all three categories in which it was nominated at
Scotland’s Life Sciences Annual Awards.